Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Edoxaban: an update on the new oral direct factor xa inhibitor.

Bounameaux H, Camm AJ.

Drugs. 2014 Jul;74(11):1209-31. doi: 10.1007/s40265-014-0261-1.

PMID:
25034361
[PubMed - in process]
Free PMC Article
2.

Edoxaban: a new oral direct factor xa inhibitor.

Camm AJ, Bounameaux H.

Drugs. 2011 Aug 20;71(12):1503-26. doi: 10.2165/11595540-000000000-00000.

PMID:
21861537
[PubMed - indexed for MEDLINE]
3.

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).

Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E.

Am Heart J. 2010 Oct;160(4):635-41. doi: 10.1016/j.ahj.2010.06.042.

PMID:
20934556
[PubMed - indexed for MEDLINE]
4.

Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.

Giugliano RP, Ruff CT, Rost NS, Silverman S, Wiviott SD, Lowe C, Deenadayalu N, Murphy SA, Grip LT, Betcher JM, Duggal A, Dave J, Shi M, Mercuri M, Antman EM, Braunwald E; ENGAGE AF-TIMI 48 Investigators.

Stroke. 2014 Aug;45(8):2372-8. doi: 10.1161/STROKEAHA.114.006025. Epub 2014 Jun 19.

PMID:
24947287
[PubMed - in process]
5.

[Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].

Sprynger M.

Rev Med Liege. 2013 Oct;68(10):548-51. French.

PMID:
24298731
[PubMed - indexed for MEDLINE]
6.

Edoxaban versus warfarin in patients with atrial fibrillation.

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators.

N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.

PMID:
24251359
[PubMed - indexed for MEDLINE]
Free Article
7.

Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.

Yamashita T, Koretsune Y, Yasaka M, Inoue H, Kawai Y, Yamaguchi T, Uchiyama S, Matsumoto M, Ogawa S.

Circ J. 2012;76(8):1840-7. Epub 2012 May 18.

PMID:
22664798
[PubMed - indexed for MEDLINE]
Free Article
8.

Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.

Morishima Y, Honda Y, Kamisato C, Shibano T.

Thromb Res. 2013 Aug;132(2):234-9. doi: 10.1016/j.thromres.2013.05.020. Epub 2013 Jun 12.

PMID:
23768448
[PubMed - indexed for MEDLINE]
9.

Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.

Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, Mercuri M; Hokusai-VTE Investigators.

J Thromb Haemost. 2013 Jul;11(7):1287-94. doi: 10.1111/jth.12230.

PMID:
23574579
[PubMed - indexed for MEDLINE]
10.

Edoxaban: Review of Pharmacology and Key Phase I to III Clinical Trials.

Plitt A, Giugliano RP.

J Cardiovasc Pharmacol Ther. 2014 Sep;19(5):409-16. doi: 10.1177/1074248414523675. Epub 2014 Mar 7.

PMID:
24607764
[PubMed - in process]
11.

Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.

Bruins Slot KM, Berge E.

Cochrane Database Syst Rev. 2013 Aug 8;8:CD008980. doi: 10.1002/14651858.CD008980.pub2. Review.

PMID:
23925867
[PubMed - indexed for MEDLINE]
12.

Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.

Chung N, Jeon HK, Lien LM, Lai WT, Tse HF, Chung WS, Lee TH, Chen SA.

Thromb Haemost. 2011 Mar;105(3):535-44. doi: 10.1160/TH10-07-0451. Epub 2010 Dec 6.

PMID:
21136011
[PubMed - indexed for MEDLINE]
13.

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P.

N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390.

PMID:
23991658
[PubMed - indexed for MEDLINE]
Free Article
14.

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.

Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I, Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M, Tachibana M, Zhou S, Rohatagi S.

Thromb Haemost. 2012 May;107(5):925-36. doi: 10.1160/TH11-08-0566. Epub 2012 Mar 8.

PMID:
22398655
[PubMed - indexed for MEDLINE]
15.

Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.

Rognoni C, Marchetti M, Quaglini S, Liberato NL.

J Thromb Thrombolysis. 2014 Jun 28. [Epub ahead of print]

PMID:
24973057
[PubMed - as supplied by publisher]
16.

Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.

Ruff CT, Giugliano RP, Braunwald E, Mercuri M, Curt V, Betcher J, Grip L, Cange AL, Crompton AE, Murphy SA, Deenadayalu N, Antman EM.

J Am Coll Cardiol. 2014 Aug 12;64(6):576-84. doi: 10.1016/j.jacc.2014.05.028.

PMID:
25104527
[PubMed - in process]
17.

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.

Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S.

Thromb Haemost. 2010 Sep;104(3):633-41. doi: 10.1160/TH10-01-0066. Epub 2010 Aug 5.

PMID:
20694273
[PubMed - indexed for MEDLINE]
18.

Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.

Deedwania PC, Huang GW.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):265-75. doi: 10.2165/11592410-000000000-00000. Review.

PMID:
21740079
[PubMed - indexed for MEDLINE]
19.

Stroke Prevention in Atrial Fibrillation [Internet].

Lopes RD, Crowley MJ, Shah BR, Melloni C, Wood KA, Chatterjee R, Povsic TJ, Dupre ME, Kong DF, de Barros e Silva PGM, dos Santos MHH, Armaganijan LV, Katz M, Kosinski A, McBroom AJ, Chobot MM, Gray R, Sanders GD.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Aug.

PMID:
24049843
[PubMed]
Books & Documents
20.

Oral anticoagulation with edoxaban. Focus on current phase III clinical development.

Ahrens I, Bode C.

Hamostaseologie. 2012;32(3):212-5. doi: 10.5482/HAMO-12-05-0004. Epub 2012 Jul 12.

PMID:
22786687
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk